RightFit
RecruitingPhase not listed

PTGS1 Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn

Prostaglandin G/H Synthase-1 (PTGS1) Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn (PPHN)

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
Up to 12 Months
Sex
All sexes
Healthy volunteers
Accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study looks at whether natural changes in a gene called PTGS-1 raise the risk of narrowing a blood vessel called the ductus arteriosus after exposure to certain over-the-counter pain medicines (NSAIDs). It includes babies born at 34 weeks or later, both healthy babies and babies with PPHN, a condition with high blood pressure in the lungs after birth.

The purpose of this study is to determine if normally occurring variations in a specific gene called PTGS-1 are associated with an increased risk of narrowing of the ductus arteriosus from exposure to over-the-counter pain medicines (NSAIDs).

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Babies born at 34 weeks of pregnancy or later.
  • Babies with PPHN or normal, healthy babies.

Who can't join

  • Birth defects that cause death.
  • Problems with the heart's structure present at birth, except PDA or patent foramen ovale (openings that normally exist before birth).
  • Problems with the structure of the stomach or intestines that could block the baby's first stool.
  • Certain birth defects: diaphragmatic hernia (a hole in the muscle below the lungs), Potter's syndrome (problems linked to too little fluid around the baby before birth), or pulmonary hypoplasia (lungs that have not fully developed).

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Infants born greater than or equal to 34 weeks gestational age diagnosed with PPHN and normal, healthy infants born greater than or equal to 34 weeks gestational age. Exclusion Criteria: * Patients will be excluded if they are diagnosed with lethal congenital anomalies * structural congenital heart disease except presence of patent ductus arteriosus (PDA) or patent foramen ovale * structural gastrointestinal tract abnormality that could interfere with meconium passage * congenital anomalies such as diaphragmatic hernia, Potter's syndrome, or pulmonary hypoplasia

Study sites (1)

WI